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At present, the dissemination of cancer cells 
– metastasis – is the primary cause of cancer 
mortality in more than 90% of cases. Whereas 
well-confined, primary cancer can be cured by 
early diagnosis, surgical resection and adjuvant 
therapy, metastatic disease is incurable in most 
cases. This is mainly because a metastasizing 
tumor is a systemic disease affecting various solid 
organs, the lymphatics as well as the immune 
system [1]. Thus, a better understanding of the 
metastatic processes will enable us to identify 
novel targets, the interference of which may lead 
to effective treatment of a cancer disease.
Hematogenous metastasis is a complex, 
sequential process during which cancer cells 
locally invade the extracellular matrix; intravasate 
into the blood vessels; survive in the circulation; 
arrest at distant organ sites; extravasate into the 
parenchyma of tissues; colonize and remodel 
the foreign microenvironment and establish 
metastatic sites [2,3]. It has initially been 
hypothesized that the accumulation of mutations 
in various signaling pathways, enabling cancer 
cells to become invasive, requires a substantial 
amount of time. However, the fact that metastatic 
cells have already been detected at early clinical 
stages of cancer speaks against this hypothesis 
but does not exclude additional scenarios [2,3].
There is a general consensus that metastatic 
cancer cells are in a constant ‘cross-talk’ with the 
local microenvironment, consisting of stromal 
cells, leukocytes and endothelial cells, and that 
this ‘communication’ modulates tumor cell 
migration at primary sites, as well as adhesion 
and survival in the circulation and growth of 
metastatic lesions at distant organs [1,4,5]. To 
invade the stroma of a primary tumor, carcinoma 
cells have to breach the basement membrane of 
epithelial cells that serves as a barrier and has a 
vital function in the organization of epithelial 
organs. Furthermore, the extracellular matrix is 
a reservoir of growth factors and other signaling 
molecules (e.g., cytokines) whose release 
by carcinoma-secreted proteases stimulates 
signaling cascades initiating cell proliferation, 
survival and invasiveness [6]. Metastasis is 
determined by dynamic interactions between 
cancer cells and diverse populations of stromal 
cells. Besides, bone marrow-derived cells 
(BMDCs) of myeloid origin are the most 
prominent cell population present in the tumor 
microenvironment, at both the primary and 
metastatic sites [4,7]. Macrophages and BMDCs 
are capable of modulating the behavior of cancer 
cells and have been shown to facilitate invasion, 
intravasation and metastasis in animal models 
[8–10]. While the contribution of BMDCs to 
metastasis is becoming more and more accepted, 
the mode of action and the underlying molecular 
mechanisms are still under investigation.
From a clinical point of view, in a large 
number of cancer patients, signs of metastasis 
(e.g., circulating tumor cells and detectable 
metastases) are already apparent at the time of 
diagnosis. Therefore, therapeutic intervention 
at time points when cancer cells are already in 
the circulation or at distant sites are of highest 
clinical relevance.
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Circulating tumor cells must acquire 
capabilities to survive a variety of stress factors 
to reach distant organs and to arrest at these 
sites. Although circulating tumor cells could 
theoretically disseminate in all organs, clinicians 
have observed that particular carcinomas 
metastasize to a limited number of tissues [1]. 
The nature of this so-called ‘tissue tropism’ 
of cancer cells remains under investigation, 
but accumulating evidence suggests that the 
‘hosting’ tissue microenvironment critically 
contributes to organ-specific metastasis [2,11]. 
Efficient cancer cell adhesion in the vasculature 
of various organs has been shown to contribute to 
metastasis efficacy, therefore cell–cell interactions 
represent useful therapeutic targets for inhibition 
of this process. Two major cell adhesion molecule 
families, the selectin and the integrin families, 
have been described to participate in the 
metastatic cascade [5]. In addition, a number of 
soluble mediators (e.g., chemokines), derived 
from tumor cells, blood constituents and the 
local microenvironment, facilitate cancer 
cell extravasation and colonization of distant 
organs [8,12,13]. Chemokines, a family of small 
and secreted proteins, play pleiotropic roles in 
the development and organization of immune 
responses, as well as in inflammatory-related 
diseases including cancer [14,15]. In particular, 
inf lammatory chemokines, such as CCL2 
and CCL5, are associated with poor prognosis 
of breast, pancreas and colon cancer due to 
metastasis, although the mechanisms of action 
remain under investigation [14–16]. CCL2- and 
CCL5-mediated recruitment of monocytes has 
been demonstrated to facilitate metastasis for 
different cancer types [8,12,17]. Recently, we have 
demonstrated that CCL2 does not only recruit 
monocytes to the sites of metastasis but, more 
importantly, enables cancer cell extravasation [13].
To investigate how CCL2 increases metastasis 
we analyzed colon cancer metastasis in mice, 
with or without expression of the chemokine 
receptor CCR2, which binds CCL2 [13]. First, 
we analyzed the homing behavior of MC-38GFP 
colon cancer cells into the lungs of C57BL/6 wild-
type (wt) and Ccr2-/- mice. Using histological 
analyses followed by 3D-reconstruction, we 
showed that MC-38GFP cells did not leave 
the vasculature in Ccr2-/- mice, while in wt 
mice tumor cells had already extravasated at 
24 h post tumor cell challenge. But what could 
have been the reason for this impaired tumor 
cell extravasation in Ccr2-/- mice? Experiments 
addressing the status of vascular integrity gave 
a clue; whereas wt mice displayed a strongly 
increased vascular permeability as determined 
by Evans blue staining, there was no increase 
in vascular permeability in Ccr2-/- mice. Using 
several techniques and different transgenic 
mice, we identified two major cell populations 
expressing CCR2: monocytes and endothelial 
cells. To define the compartment controlling 
tumor cell extravasation, we performed 
reciprocal reconstitution experiments with wt 
and Ccr2-/- mice. We confirmed that CCR2+ 
monocytes/macrophages supported tumor cell 
metastasis as described previously [8]. However, 
most unexpectedly, we identif ied CCR2 
expression on endothelial cells as a critical 
factor for efficient tumor cell extravasation and 
therefore metastasis.
“In the last decade, prevention of tumor 
cell metastasis has become one of the 
most important scientific and clinical 
aims of cancer research.”
It was not clear whether chemokines activating 
CCR2 (e.g., CCL2 or CCL7) were produced 
by host or tumor cells. This question was first 
analyzed in Ccl2-/- mice, which demonstrated 
lung vascular permeability comparable with 
wt mice upon tumor cell challenge. Thus, 
CCL2 produced by host cells was not required 
for increased vascular permeability, indicating 
cancer cells to be the source of CCL2. Indeed, 
MC-38GFP cells, as well as Lewis lung carcinoma 
cells, expressed high levels of CCL2, which was 
associated with increased metastasis. Therefore, 
we hypothesized a link between CCL2 expression 
on tumor cells and the acquired capacity of tumor 
cells to successfully extravasate into the lungs. To 
address this point experimentally, we generated 
MC-38 and Lewis lung carcinoma  cells with a 
CCL2 knockdown. Indeed, efficient knockdown 
of CCL2 in both cell lines abrogated their capacity 
to induce vascular permeability and to efficiently 
metastasize in vivo. Thus, CCL2 expression in 
cancer cells induces vascular permeability via 
CCR2 expressed on endothelial cells, which 
enables efficient tumor cell extravasation.
Finally, we wanted to address the cellular and 
molecular mechanism(s) of CCL2–CCR2-
induced cancer cell extravasation. With the 
use of an in vitro system and various inhibitors 
we investigated the involvement of signaling 
cascades in cancer cell extravasation downstream 
of CCR2. These experiments revealed that, 
upon CCR2 activation by tumor cell-derived 
CCL2, JAK2 is phosphorylated, further 
activating downstream Stat5. In addition, p38 
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is also activated in order to support efficient 
tumor cell extravasation. As p38 activation was 
independent from JAK2 activation, the signaling 
cascade activating p38 is yet to be defined. Other 
pathways, such Stat5, Rac1 and PI3Kg, could be 
excluded. Our data describe, for the first time, 
that cancer cell-derived chemokines can activate 
chemokine receptors (e.g., CCR2) on endothelial 
cells, and thereby enable efficient tumor cell 
extravasation. Downstream of CCR2, two 
independent pathways – in a timely staggered 
fashion – enable chemokine-driven metastasis. 
Future experiments will identify the origin of 
the p38-mediated pathway and the exact cellular 
kinetics of transmigration.
In the last decade, prevention of tumor cell 
metastasis has become one of the most important 
scientific and clinical aims of cancer research. It 
is therefore not unexpected that accumulating 
a wealth of data could, at some stage, lead to 
successful clinical applications. However, efficient 
inhibition of established or ongoing metastasis 
by targeting tumor cells is currently a highly 
complicated and so far unachieved endeavor. 
Various important points, such as the different 
behaviors of the distinct tumor types and the 
pleiotropic/systemic effects of chemokines and 
other factors (e.g., growth factors and cytokines), 
have to be addressed first in order to gain a 
complete understanding of the metastatic process.
“...efficient inhibition of established or 
ongoing metastasis by targeting tumor 
cells is currently a highly complicated 
and so far unachieved endeavor.” 
Since cancer metastasis is a cascade of 
sequential and interlinked events, inhibition of 
a single step may not be sufficient to completely 
block metastasis. Furthermore, the time windows 
to block metastasizing cells from adhering and 
extravasating into distant organs might be very 
small, which is supported by experimental 
evidence [1,5]. Depending on the stage, cancer 
patients display a high number of circulating 
tumor cells and metastasis, therefore a therapy 
aimed at preventing cancer cell extravasation may 
strongly reduce the risk of new metastasis, but 
may not prevent the development of small, already 
established ones. Nevertheless, accumulating 
experimental evidence strongly suggests that 
the interference in cancer cell communication 
with the microenvironment (e.g., through 
CCL2) leads to attenuation of metastasis in a 
number of animal models [8,13,17,18]. Based on 
this preclinical evidence, two clinical trials have 
been initiated, evaluating the safety and efficacy 
of blocking both CCL2 and CCR2 in metastatic 
patients [101,102]. The initial trial blocking CCL2 
proved to be less effective, possibly due to an 
induced compensatory mechanism that led 
to an increase of CCL2 expression. The trial 
targeting CCR2 is currently ongoing. Further 
clinical trials addressing cancer types associated 
with high expression of CCL2 and/or CCL5 will 
test the potential of targeting these chemokines 
as a potential antimetastatic treatment. Of note, 
there is currently no antimetastatic therapy 
clinically available, therefore additional criteria 
assessing therapy efficacy will be required. 
Finally, based on the current understanding of 
the involvement of chemokines in metastasis, 
cancer patients should be treated from the time 
of identification of a tumor that is likely to be 
metastatic, through postoperational treatment.
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